Alliaceumolide A: A rare undescribed 17-membered macrolide from Indonesian Dysoxylum alliaceum

IF 1.3 4区生物学 Q4 CHEMISTRY, MEDICINAL

Phytochemistry Letters Pub Date : 2024-07-17 DOI:10.1016/j.phytol.2024.07.004

Sandra Amalia Riyadi , Al Arofatus Naini , Tri Mayanti , Kindi Farabi , Desi Harneti , Nurlelasari , Rani Maharani , Ronny Lesmana , Sofa Fajriah , Siriporn Jungsuttiwong , Khalijah Awang , Mohamad Nurul Azmi , Unang Supratman

引用次数: 0

Abstract

Alliaceumolide A (1), a new macrolide together with known ivorenolide B (2) were isolated from Dysoxylum alliaceum (Blume) Blume ex A.Juss. These compounds were classified as 17-membered macrolide, which is a rare structure for plant-derived natural products. The structures were elucidated by extensive spectroscopic analyses, and the absolute configuration of 1 was determined by electronic circular dichroism (ECD) using TDDFT method. Furthermore, compounds 1 and 2 were tested for cytotoxic activity against two cancer MCF-7 and HeLa cell lines.

查看原文本刊更多论文

Alliaceumolide A：来自印度尼西亚 Dysoxylum alliaceum 的一种罕见的未被描述的 17 元大环内酯

从Dysoxylum alliaceum (Blume) Blume ex A.Juss.中分离出了一种新的大环内酯--Alliaceumolide A（1）和已知的ivorenolide B（2）。这些化合物被归类为 17 元大环内酯类化合物，这是植物源天然产物中罕见的结构。通过大量光谱分析阐明了这些化合物的结构，并利用 TDDFT 方法通过电子圆二色性（ECD）确定了 1 的绝对构型。此外，还测试了化合物 1 和 2 对 MCF-7 和 HeLa 两种癌症细胞系的细胞毒性活性。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

Phytochemistry Letters 生物-生化与分子生物学

CiteScore

3.00

自引率

11.80%

发文量

190

审稿时长

34 days

期刊介绍： Phytochemistry Letters invites rapid communications on all aspects of natural product research including: • Structural elucidation of natural products • Analytical evaluation of herbal medicines • Clinical efficacy, safety and pharmacovigilance of herbal medicines • Natural product biosynthesis • Natural product synthesis and chemical modification • Natural product metabolism • Chemical ecology • Biotechnology • Bioassay-guided isolation • Pharmacognosy • Pharmacology of natural products • Metabolomics • Ethnobotany and traditional usage • Genetics of natural products Manuscripts that detail the isolation of just one new compound are not substantial enough to be sent out of review and are out of scope. Furthermore, where pharmacology has been performed on one new compound to increase the amount of novel data, the pharmacology must be substantial and/or related to the medicinal use of the producing organism.